- Home
- ROIV vs XP Comparison
ROIV vs XP Comparison
Compare ROIV & XP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ROIV | XP |
|---|---|---|
| Founded | 2014 | 2001 |
| Country | United Kingdom | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1B | 10.1B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | ROIV | XP |
|---|---|---|
| Price | $22.13 | $17.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | $21.94 | ★ $22.40 |
| AVG Volume (30 Days) | 6.7M | ★ 8.8M |
| Earning Date | 11-10-2025 | 11-17-2025 |
| Dividend Yield | N/A | ★ 1.03% |
| EPS Growth | N/A | ★ 18.53 |
| EPS | N/A | ★ 1.76 |
| Revenue | $20,329,000.00 | ★ $3,229,174,949.00 |
| Revenue This Year | N/A | $17.71 |
| Revenue Next Year | $376.94 | $13.05 |
| P/E Ratio | ★ N/A | $9.92 |
| Revenue Growth | N/A | ★ 8.33 |
| 52 Week Low | $8.73 | $10.82 |
| 52 Week High | $22.45 | $20.64 |
Technical Indicators
Market Signals| Indicator | ROIV | XP |
|---|---|---|
| Relative Strength Index (RSI) | 68.21 | 43.14 |
| Support Level | $20.14 | $17.52 |
| Resistance Level | $21.48 | $20.06 |
| Average True Range (ATR) | 0.66 | 0.71 |
| MACD | -0.02 | -0.19 |
| Stochastic Oscillator | 87.12 | 5.95 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About XP XP Inc.
XP Inc is a Cayman Island-based technology-driven financial services platform. It is a provider of low-fee financial products and services in Brazil. The company evaluates its business through a single segment such as monitoring operations, making decisions on fund allocation, and evaluating the performance. It generates revenue through the Brokerage commission.